Diabetes Care, Vol 19, Issue 7 726-729, Copyright © 1996 by American Diabetes Association

ARTICLES

Comparisons of studies on diabetic complications hampered by differences in GHb measurements

CE Kullberg, A Bergstrom, B Dinesen, L Larsson, RR Little, DE Goldstein and HJ Arnqvist
Department of Internal Medicine, Faculty of Health Sciences, Linkoping, Sweden.

OBJECTIVE: To compare glycated hemoglobin (GHb) values of the relationship between glycemic control and complications of diabetes from laboratories involved in long-term studies (Steno, Oslo, Stockholm, Diabetes Control and Complications Trial, and Linkoping.) RESEARCH DESIGN AND METHODS: Blood samples were collected from 25 subjects selected to represent the clinically relevant measurement range. Fresh whole-blood samples were distributed and analyzed within 4 days of sample collection. Pretreatment of samples and analyses of GHb were performed according to the routine method of each study's central or reference laboratory. Results from each laboratory were compared with the group mean, i.e., the mean of all results for each sample. RESULTS: Regression analyses with the group mean values as independent variables and results from each laboratory as dependent variables showed that Oslo's result had a slope significantly different from the group mean. Laboratories used by the DCCT, Oslo, and Steno studies gave, on average, 0.4, 0.4, and 0.7% higher HbA1c readings than the group mean, respectively, while HbA1c results from Linkoping and Stockholm were, on average, 0.6 and 1.0% lower, respectively. CONCLUSIONS: There were large differences in GHb values among laboratories participating in studies of diabetic complications. The present data offer a guide to the comparison of results from the studies and underscores the need for standardization of GHb measurements.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. A. Hedman, J. Frystyk, T. Lindstrom, J.-W. Chen, A. Flyvbjerg, H. Orskov, and H. J Arnqvist Residual {beta}-Cell Function More than Glycemic Control Determines Abnormalities of the Insulin-Like Growth Factor System in Type 1 Diabetes J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6305 - 6309. [Abstract] [Full Text] [PDF]

				M. Svensson, J. W. Eriksson, and G. Dahlquist Early Glycemic Control, Age at Onset, and Development of Microvascular Complications in Childhood-Onset Type 1 Diabetes: A population-based study in northern Sweden Diabetes Care, April 1, 2004; 27(4): 955 - 962. [Abstract] [Full Text] [PDF]

				J. Ludvigsson and R. Hanas Continuous Subcutaneous Glucose Monitoring Improved Metabolic Control in Pediatric Patients With Type 1 Diabetes: A Controlled Crossover Study Pediatrics, May 1, 2003; 111(5): 933 - 938. [Abstract] [Full Text] [PDF]

				M. Henricsson, L. Nystrom, G. Blohme, J. Ostman, C. Kullberg, M. Svensson, A. Scholin, H. J. Arnqvist, E. Bjork, J. Bolinder, et al. The Incidence of Retinopathy 10 Years After Diagnosis in Young Adult People With Diabetes: Results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS) Diabetes Care, February 1, 2003; 26(2): 349 - 354. [Abstract] [Full Text] [PDF]

				T. Lindstrom, C. A. Hedman, and H. J. Arnqvist Use of a Novel Double-Antibody Technique to Describe the Pharmacokinetics of Rapid-Acting Insulin Analogs Diabetes Care, June 1, 2002; 25(6): 1049 - 1054. [Abstract] [Full Text] [PDF]

				M. Bojestig, B. E. Karlberg, T. Lindström, and F. H. Nystrom Reduction of ACE Activity Is Insufficient to Decrease Microalbuminuria in Normotensive Patients With Type 1 Diabetes Diabetes Care, May 1, 2001; 24(5): 919 - 924. [Abstract] [Full Text]

				R. C. Perry, R. R. Shankar, N. Fineberg, J. McGill, and A. D. Baron HbA1c Measurement Improves the Detection of Type 2 Diabetes in High-Risk Individuals With Nondiagnostic Levels of Fasting Plasma Glucose: The Early Diabetes Intervention Program (EDIP) Diabetes Care, March 1, 2001; 24(3): 465 - 471. [Abstract] [Full Text]